查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1139895

人类乳突病毒疫苗市场:各类型，各疾病适应症，各业界:全球机会分析及产业预测，2021-2030年

Human Papillomavirus Vaccine Market By Type, By Disease Indication, By Industry Vertical : Global Opportunity Analysis and Industry Forecast, 2021-2030
出版日期: | 出版商: Allied Market Research | 英文 250 Pages | 商品交期: 2-3个工作天内

价格

人类乳突病毒疫苗的全球市场规模，2021年达到38亿9270万美金，预计2030年达108亿2300万美元，从2022年到2030年的年复合成长率以12.4％的年复合成长率成长。

随着人类乳突病毒疾病的流行扩大，人类乳突病毒疫苗的市场也扩大。新的人类乳突病毒(HPV)疫苗的开发，及早期诊察和对疫苗接种的政府机关和商业团体的配合措施增加，造成人类乳突病毒(HPV)疫苗市场发展。HPV对肛门，口腔咽，生殖器领域的相关恶性肿瘤的发生率上升，和有助于减少感染疾病的人类乳突病毒(HPV)疫苗接种的需求增加，预计今后数年，维持市场稳定的成长。

目录

第1章 简介

第2章 摘要整理

第3章 市场概要

  • 市场定义和范围
  • 主要调查结果
    • 主要的投资口袋
  • 波特的五力分析
  • 主要企业的定位
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • COVID-19 影响分析
  • 价值链分析
  • 主要的法规的分析
  • 专利形势
  • 法规指南
  • 市场占有率分析

第4章 人类乳突病毒疫苗市场:各类型

  • 概要
    • 市场规模及预测
  • 4价值疫苗
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国
  • 非原子价值
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国
  • 二价
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国

第5章 人类乳突病毒疫苗市场: 各疾病适应症

  • 概要
    • 市场规模、预测
  • 子宫颈癌症
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国
  • 肛门癌
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国
  • 外阴癌、阴道癌
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国
  • 阴茎癌
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国
  • 口咽癌(Oropharyngeal Cancer
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国
  • 其他
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国

第6章 人类乳突病毒疫苗市场:各业界

  • 概要
    • 市场规模及预测
  • 公民营联盟
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测: 各地区
    • 市场分析:各国分析
  • 政府机关
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国
  • 医生
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国
  • 其他
    • 主要的市场趋势，成长要素，机会
    • 市场规模、预测:各地区
    • 市场分析:各国

第7章 人类乳突病毒疫苗市场:各地区

  • 概要
    • 市场规模及预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模、预测:各类型
    • 北美市场规模、预测:各疾病适应症
    • 北美市场规模、预测:各业界
    • 北美市场规模、预测:各国
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模、预测:各类型
    • 欧洲市场规模、预测:各疾病适应症
    • 欧洲市场规模、预测:各业界
    • 欧洲市场规模、预测:各国
      • 德国
      • 英国
      • 法国
      • 西班牙
      • 义大利
      • 其他的欧洲地区
  • 亚太地区
    • 主要趋势和机会
    • 亚太地区的市场规模、预测:各类型
    • 亚太地区的市场规模、预测:各疾病适应症
    • 亚太地区的市场规模、预测:各业界
    • 亚太地区的市场规模、预测:各国
      • 中国
      • 日本
      • 印度
      • 韩国
      • 澳洲
      • 其他亚太地区
  • LAMEA
    • 主要趋势和机会
    • LAMEA的市场规模、预测:各类型
    • LAMEA的市场规模、预测:各疾病适应症
    • LAMEA的市场规模、预测:各业界
    • LAMEA的市场规模、预测:各国
      • 巴西
      • 沙乌地阿拉伯
      • 阿拉伯联合大公国
      • 南非
      • LAMEA的其余地区

第8章 企业形势

  • 简介
  • 主要成功策略
  • 主要十大公司的产品製图
  • 竞争仪表板
  • 竞争的热图
  • 主要的发展

第9章 企业简介

  • Merck & Co., Inc
  • GlaxoSmithKline plc.
  • Sanofi
  • Johnson & Johnson
  • AstraZeneca
  • Serum Institute of India Pvt. Ltd
  • Bharat Biotech.
  • Xenetic Biosciences, Inc.
  • Inovio Pharmaceuticals, Inc
  • Novartis AG
Product Code: A14328

The global human papillomavirus vaccine market size was valued at $3,892.7 million in 2021 and is projected to reach $10,823.0 million by 2030, growing at a CAGR of 12.4% from 2022 to 2030.    

As the prevalence of human papillomavirus diseases grows, so does the market for human papillomavirus vaccines. The development of new HPV vaccines, as well as increased initiatives by government and commercial organizations for early screening and vaccination, are propelling the human papillomavirus (HPV) vaccine market forward. The rising incidence of HPV-related malignancies in the anal, oropharynx, and genital regions, as well as increased demand for HPV vaccinations to help decrease infections, are expected to keep the market growing steadily in the coming years.

Healthcare expenditures, on the other hand, are skyrocketing, with the drive toward prevention. Vaccination costs have risen from the single digits to triple digits several times over the last two decades, posing considerable issues for doctors and their patients while also putting a strain on public health funding.

The global human papillomavirus vaccine market trends is segmented on the basis of type, disease indication, industry vertical and region. Based on type, the market has been divided into tetravalent, nonavalent, and bivalent. Based on disease indication, the market has been divided into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. Based on industry vertical, the market has been divided into public and private alliances, government entities, physicians, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in this report include: GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Sanofi S.A., Novartis AG, Serum Institute of India Pvt. Ltd., Bharat Biotech, Inovio Pharmaceuticals, Inc and Xenetic Biosciences, Inc. among others.

Key Market Segments

By Type

  • Tetravalent
  • Nonavalent
  • Bivalent

By Disease Indication

  • Cervical Cancer
  • Anal Cancer
  • Vulvar Vaginal Cancer
  • Penile Cancer
  • Oropharyngeal Cancer
  • Others

By Industry Vertical

  • Public and Private Alliances
  • Government Entities
  • Physicians
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • United Arab Emirates
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Merck & Co., Inc
    • GlaxoSmithKline plc.
    • Sanofi
    • Johnson & Johnson
    • AstraZeneca
    • Serum Institute of India Pvt. Ltd
    • Bharat Biotech.
    • Xenetic Biosciences, Inc.
    • Inovio Pharmaceuticals, Inc
    • Novartis AG

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Value Chain Analysis
  • 3.8.Key Regulation Analysis
  • 3.9.Patent Landscape
  • 3.10.Regulatory Guidelines
  • 3.11.Market Share Analysis

CHAPTER 4: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Tetravalent
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Nonavalent
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Bivalent
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Cervical Cancer
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Anal Cancer
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Vulvar & Vaginal Cancer
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Penile Cancer
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country
  • 5.6 Oropharyngeal Cancer
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market analysis by country
  • 5.7 Others
    • 5.7.1 Key market trends, growth factors and opportunities
    • 5.7.2 Market size and forecast, by region
    • 5.7.3 Market analysis by country

CHAPTER 6: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Public and Private Alliances
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Government Entities
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Physicians
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country
  • 6.5 Others
    • 6.5.1 Key market trends, growth factors and opportunities
    • 6.5.2 Market size and forecast, by region
    • 6.5.3 Market analysis by country

CHAPTER 7: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
    • 7.2.3 North America Market size and forecast, by Disease Indication
    • 7.2.4 North America Market size and forecast, by Industry Vertical
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Type
      • 7.2.5.1.2 Market size and forecast, by Disease Indication
      • 7.2.5.1.3 Market size and forecast, by Industry Vertical
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Type
      • 7.2.5.2.2 Market size and forecast, by Disease Indication
      • 7.2.5.2.3 Market size and forecast, by Industry Vertical
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Type
      • 7.2.5.3.2 Market size and forecast, by Disease Indication
      • 7.2.5.3.3 Market size and forecast, by Industry Vertical
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
    • 7.3.3 Europe Market size and forecast, by Disease Indication
    • 7.3.4 Europe Market size and forecast, by Industry Vertical
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Type
      • 7.3.5.1.2 Market size and forecast, by Disease Indication
      • 7.3.5.1.3 Market size and forecast, by Industry Vertical
      • 7.3.5.2 United Kingdom
      • 7.3.5.2.1 Market size and forecast, by Type
      • 7.3.5.2.2 Market size and forecast, by Disease Indication
      • 7.3.5.2.3 Market size and forecast, by Industry Vertical
      • 7.3.5.3 France
      • 7.3.5.3.1 Market size and forecast, by Type
      • 7.3.5.3.2 Market size and forecast, by Disease Indication
      • 7.3.5.3.3 Market size and forecast, by Industry Vertical
      • 7.3.5.4 Spain
      • 7.3.5.4.1 Market size and forecast, by Type
      • 7.3.5.4.2 Market size and forecast, by Disease Indication
      • 7.3.5.4.3 Market size and forecast, by Industry Vertical
      • 7.3.5.5 Italy
      • 7.3.5.5.1 Market size and forecast, by Type
      • 7.3.5.5.2 Market size and forecast, by Disease Indication
      • 7.3.5.5.3 Market size and forecast, by Industry Vertical
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Type
      • 7.3.5.6.2 Market size and forecast, by Disease Indication
      • 7.3.5.6.3 Market size and forecast, by Industry Vertical
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Disease Indication
    • 7.4.4 Asia-Pacific Market size and forecast, by Industry Vertical
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 China
      • 7.4.5.1.1 Market size and forecast, by Type
      • 7.4.5.1.2 Market size and forecast, by Disease Indication
      • 7.4.5.1.3 Market size and forecast, by Industry Vertical
      • 7.4.5.2 Japan
      • 7.4.5.2.1 Market size and forecast, by Type
      • 7.4.5.2.2 Market size and forecast, by Disease Indication
      • 7.4.5.2.3 Market size and forecast, by Industry Vertical
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Type
      • 7.4.5.3.2 Market size and forecast, by Disease Indication
      • 7.4.5.3.3 Market size and forecast, by Industry Vertical
      • 7.4.5.4 South Korea
      • 7.4.5.4.1 Market size and forecast, by Type
      • 7.4.5.4.2 Market size and forecast, by Disease Indication
      • 7.4.5.4.3 Market size and forecast, by Industry Vertical
      • 7.4.5.5 Australia
      • 7.4.5.5.1 Market size and forecast, by Type
      • 7.4.5.5.2 Market size and forecast, by Disease Indication
      • 7.4.5.5.3 Market size and forecast, by Industry Vertical
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Type
      • 7.4.5.6.2 Market size and forecast, by Disease Indication
      • 7.4.5.6.3 Market size and forecast, by Industry Vertical
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
    • 7.5.3 LAMEA Market size and forecast, by Disease Indication
    • 7.5.4 LAMEA Market size and forecast, by Industry Vertical
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Type
      • 7.5.5.1.2 Market size and forecast, by Disease Indication
      • 7.5.5.1.3 Market size and forecast, by Industry Vertical
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Type
      • 7.5.5.2.2 Market size and forecast, by Disease Indication
      • 7.5.5.2.3 Market size and forecast, by Industry Vertical
      • 7.5.5.3 United Arab Emirates
      • 7.5.5.3.1 Market size and forecast, by Type
      • 7.5.5.3.2 Market size and forecast, by Disease Indication
      • 7.5.5.3.3 Market size and forecast, by Industry Vertical
      • 7.5.5.4 South Africa
      • 7.5.5.4.1 Market size and forecast, by Type
      • 7.5.5.4.2 Market size and forecast, by Disease Indication
      • 7.5.5.4.3 Market size and forecast, by Industry Vertical
      • 7.5.5.5 Rest of LAMEA
      • 7.5.5.5.1 Market size and forecast, by Type
      • 7.5.5.5.2 Market size and forecast, by Disease Indication
      • 7.5.5.5.3 Market size and forecast, by Industry Vertical

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Merck & Co., Inc
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 GlaxoSmithKline plc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Sanofi
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Johnson & Johnson
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 AstraZeneca
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Serum Institute of India Pvt. Ltd
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Bharat Biotech.
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Xenetic Biosciences, Inc.
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Inovio Pharmaceuticals, Inc
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Novartis AG
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 2. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR TETRAVALENT, BY REGION, 2021-2030 ($MILLION)
  • TABLE 3. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR TETRAVALENT, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 4. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR NONAVALENT, BY REGION, 2021-2030 ($MILLION)
  • TABLE 5. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR NONAVALENT, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 6. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR BIVALENT, BY REGION, 2021-2030 ($MILLION)
  • TABLE 7. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR BIVALENT, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 9. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR CERVICAL CANCER, BY REGION, 2021-2030 ($MILLION)
  • TABLE 10. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR CERVICAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 11. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR ANAL CANCER, BY REGION, 2021-2030 ($MILLION)
  • TABLE 12. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR ANAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 13. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR VULVAR & VAGINAL CANCER, BY REGION, 2021-2030 ($MILLION)
  • TABLE 14. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR VULVAR & VAGINAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 15. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR PENILE CANCER, BY REGION, 2021-2030 ($MILLION)
  • TABLE 16. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR PENILE CANCER, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 17. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR OROPHARYNGEAL CANCER, BY REGION, 2021-2030 ($MILLION)
  • TABLE 18. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR OROPHARYNGEAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 19. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR OTHERS, BY REGION, 2021-2030 ($MILLION)
  • TABLE 20. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR OTHERS, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 22. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR PUBLIC AND PRIVATE ALLIANCES, BY REGION, 2021-2030 ($MILLION)
  • TABLE 23. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR PUBLIC AND PRIVATE ALLIANCES, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 24. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR GOVERNMENT ENTITIES, BY REGION, 2021-2030 ($MILLION)
  • TABLE 25. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR GOVERNMENT ENTITIES, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 26. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR PHYSICIANS, BY REGION, 2021-2030 ($MILLION)
  • TABLE 27. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR PHYSICIANS, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 28. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR OTHERS, BY REGION, 2021-2030 ($MILLION)
  • TABLE 29. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR OTHERS, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 30. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY REGION, 2021-2030 ($MILLION)
  • TABLE 31. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 32. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 33. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 34. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 35. U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 36. U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 37. U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 38. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 39. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 40. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 41. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 42. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 43. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 44. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 45. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 46. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 47. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 48. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 49. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 50. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 51. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 52. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 53. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 54. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 55. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 56. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 57. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 58. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 59. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 60. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 61. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 62. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 63. REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 64. REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 65. REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 66. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 67. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 68. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 69. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 70. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 71. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 72. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 73. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 74. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 75. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 76. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 77. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 78. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 79. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 80. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 81. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 82. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 83. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 84. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 85. REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 86. REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 87. REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 88. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 89. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 90. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 91. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 92. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 93. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 94. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 95. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 96. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 97. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 98. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 99. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 100. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 101. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 102. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 103. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 104. REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
  • TABLE 105. REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
  • TABLE 106. REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
  • TABLE 107.MERCK & CO., INC: COMPANY SNAPSHOT
  • TABLE 108.MERCK & CO., INC: OPERATING SEGMENTS
  • TABLE 109.MERCK & CO., INC: PRODUCT PORTFOLIO
  • TABLE 110.MERCK & CO., INC: NET SALES,
  • TABLE 111.MERCK & CO., INC: KEY STRATERGIES
  • TABLE 112.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 113.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 114.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 115.GLAXOSMITHKLINE PLC.: NET SALES,
  • TABLE 116.GLAXOSMITHKLINE PLC.: KEY STRATERGIES
  • TABLE 117.SANOFI: COMPANY SNAPSHOT
  • TABLE 118.SANOFI: OPERATING SEGMENTS
  • TABLE 119.SANOFI: PRODUCT PORTFOLIO
  • TABLE 120.SANOFI: NET SALES,
  • TABLE 121.SANOFI: KEY STRATERGIES
  • TABLE 122.JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 123.JOHNSON & JOHNSON: OPERATING SEGMENTS
  • TABLE 124.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 125.JOHNSON & JOHNSON: NET SALES,
  • TABLE 126.JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 127.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 128.ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 129.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 130.ASTRAZENECA: NET SALES,
  • TABLE 131.ASTRAZENECA: KEY STRATERGIES
  • TABLE 132.SERUM INSTITUTE OF INDIA PVT. LTD: COMPANY SNAPSHOT
  • TABLE 133.SERUM INSTITUTE OF INDIA PVT. LTD: OPERATING SEGMENTS
  • TABLE 134.SERUM INSTITUTE OF INDIA PVT. LTD: PRODUCT PORTFOLIO
  • TABLE 135.SERUM INSTITUTE OF INDIA PVT. LTD: NET SALES,
  • TABLE 136.SERUM INSTITUTE OF INDIA PVT. LTD: KEY STRATERGIES
  • TABLE 137.BHARAT BIOTECH.: COMPANY SNAPSHOT
  • TABLE 138.BHARAT BIOTECH.: OPERATING SEGMENTS
  • TABLE 139.BHARAT BIOTECH.: PRODUCT PORTFOLIO
  • TABLE 140.BHARAT BIOTECH.: NET SALES,
  • TABLE 141.BHARAT BIOTECH.: KEY STRATERGIES
  • TABLE 142.XENETIC BIOSCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 143.XENETIC BIOSCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 144.XENETIC BIOSCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 145.XENETIC BIOSCIENCES, INC.: NET SALES,
  • TABLE 146.XENETIC BIOSCIENCES, INC.: KEY STRATERGIES
  • TABLE 147.INOVIO PHARMACEUTICALS, INC: COMPANY SNAPSHOT
  • TABLE 148.INOVIO PHARMACEUTICALS, INC: OPERATING SEGMENTS
  • TABLE 149.INOVIO PHARMACEUTICALS, INC: PRODUCT PORTFOLIO
  • TABLE 150.INOVIO PHARMACEUTICALS, INC: NET SALES,
  • TABLE 151.INOVIO PHARMACEUTICALS, INC: KEY STRATERGIES
  • TABLE 152.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 153.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 154.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 155.NOVARTIS AG: NET SALES,
  • TABLE 156.NOVARTIS AG: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.HUMAN PAPILLOMAVIRUS VACCINE MARKET SEGMENTATION
  • FIGURE 2.HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030
  • FIGURE 3.HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.HUMAN PAPILLOMAVIRUS VACCINE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.VALUE CHAIN ANALYSIS
  • FIGURE 13.KEY REGULATION ANALYSIS
  • FIGURE 14.PATENT ANALYSIS BY COMPANY
  • FIGURE 15.PATENT ANALYSIS BY COUNTRY
  • FIGURE 16.REGULATORY GUIDELINES
  • FIGURE 17.MARKET SHARE ANALYSIS
  • FIGURE 18.HUMAN PAPILLOMAVIRUS VACCINE MARKET,BY TYPE,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TETRAVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF NONAVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF BIVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 22.HUMAN PAPILLOMAVIRUS VACCINE MARKET,BY DISEASE INDICATION,2021(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ANAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF VULVAR & VAGINAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF PENILE CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OROPHARYNGEAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 28.COMPARATIVE SHARE ANALYSIS OF OTHERS HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 29.HUMAN PAPILLOMAVIRUS VACCINE MARKET,BY INDUSTRY VERTICAL,2021(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF PUBLIC AND PRIVATE ALLIANCES HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 31.COMPARATIVE SHARE ANALYSIS OF GOVERNMENT ENTITIES HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 32.COMPARATIVE SHARE ANALYSIS OF PHYSICIANS HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 33.COMPARATIVE SHARE ANALYSIS OF OTHERS HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
  • FIGURE 34.HUMAN PAPILLOMAVIRUS VACCINE MARKET BY REGION,2021
  • FIGURE 35.U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 36.CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 37.MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 38.GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 39.UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 40.FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 41.SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 42.ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 43.REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 44.CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 45.JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 46.INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 47.SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 48.AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 49.REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 50.BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 51.SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 52.UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 53.SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 54.REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
  • FIGURE 55. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 56. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 57. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 58.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 59.COMPETITIVE DASHBOARD
  • FIGURE 60.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 61.MERCK & CO., INC.: NET SALES ,($MILLION)
  • FIGURE 62.GLAXOSMITHKLINE PLC..: NET SALES ,($MILLION)
  • FIGURE 63.SANOFI.: NET SALES ,($MILLION)
  • FIGURE 64.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
  • FIGURE 65.ASTRAZENECA.: NET SALES ,($MILLION)
  • FIGURE 66.SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES ,($MILLION)
  • FIGURE 67.BHARAT BIOTECH..: NET SALES ,($MILLION)
  • FIGURE 68.XENETIC BIOSCIENCES, INC..: NET SALES ,($MILLION)
  • FIGURE 69.INOVIO PHARMACEUTICALS, INC.: NET SALES ,($MILLION)
  • FIGURE 70.NOVARTIS AG.: NET SALES ,($MILLION)